niclosamide / Generic mfg. - LARVOL DELTA

Old Molecules, New Hope: A Scoping Review and Bibliometric Analysis of Drug Repurposing for Lung Cancer. (PubMed, Chem Biol Interact) - "Frequently studied drugs included niclosamide, metformin, atorvastatin, and doxazosin, targeting pathways such as PI3K/AKT/mTOR, apoptosis, and autophagy. Progress in this field depends on integrating diverse methodologies and fostering interdisciplinary collaboration. As a next step, rigorous clinical trials are essential to confirm the efficacy and safety of promising repurposed agents in oncology."

Journal • Review • CNS Disorders • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

Colistin-stabilized antisolvent precipitation enables engineering of microcrystalline niclosamide for inhalable composite powders. (PubMed, Int J Pharm) - "Finally, a preliminary in vivo lung infection model was used to assess the feasibility of pulmonary administration and the antibacterial response of the co-processed formulation relative to a standard-of-care comparator. Together, these results establish a particle-engineering platform for producing high-drug-loading niclosamide-colistin inhalation powders, highlighting how one active ingredient can function as a processing aid for excipient-minimized co-delivery of antibiotic combinations."

Journal • Cystic Fibrosis • Genetic Disorders • Immunology • Infectious Disease • Pulmonary Disease • Respiratory Diseases

EXPERIMENTAL STUDIES ON THE NEUROPROTECTIVE EFFECTS OF NICLOSAMIDE AND MOMORDICA CHARANTIA ON AUTOPHAGIC AND NF-ΚB SIGNALING PATHWAY IN MPTP-INDUCED PARKINSON'S DISEASE MODELS (ADPD 2026) - "Niclosamide and MC extract demonstrated synergistic neuroprotective effects in PD models. Their ability to reduce oxidative stress, inflammation, and dopaminergic neuron loss suggests therapeutic potential. This study supports further exploration of combined natural and pharmacological interventions for PD management."

CNS Disorders • Inflammation • Movement Disorders • Neuroblastoma • Parkinson's Disease • Solid Tumor • CAT • IL1B • TNFA

Development of niclosamide-based COVID-19 therapeutic agent using porous silicon nanoparticles. (PubMed, Nanotechnology) - "Results demonstrated that niclosamide-loaded pSiNP-NH 2 significantly suppressed viral replication more efficiently than free niclosamide at equivalent doses, while minimizing host cell cytotoxicity. These findings suggest that pSiNP-NH 2 could serve as a potent drug delivery platform, improving the therapeutic index of niclosamide for COVID-19 treatment."

Journal • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Discovery of Niclosamide Analogs with Potent Mitochondrial Uncoupling Activity and Reduced Mitochondrial Inhibition-Associated Toxicity. (PubMed, ACS Med Chem Lett) - "QSAR analysis revealed that substitution electronic properties and ring-specific hydrophobicity are related to the therapeutic index. These findings expand niclosamide's therapeutic window through rational scaffold tuning, enabling safer mitochondrial reprogramming strategies for cancer therapy."

Journal • Oncology

Multiphysics insights into flow-assisted electrochemical sensing of niclosamide: effects of surface fouling and regeneration. (PubMed, RSC Adv) - "The proposed model shows excellent agreement with experimental data, yielding a root mean square error of 0.069. Overall, this study develops a quantitative multiphysics modeling framework to analyze the coupled roles of hydrodynamics, electrochemical kinetics, and surface fouling in flow-assisted niclosamide sensing."

Journal

Dual ligand grafted liposomes for CD44 and CD206 targeted delivery of niclosamide against bisphenol A-induced hepatic fibrosis in albino Wistar rats: In vivo therapeutic efficacy and molecular pathway modulation. (PubMed, Naunyn Schmiedebergs Arch Pharmacol) - "These findings indicate the therapeutic potential of ligand-targeted liposomal delivery of NIC in reversing hepatic fibrosis. NIC-HA-MN-Lipo demonstrated potential antifibrotic effects in BPA-induced liver injury by effectively targeting key fibrogenic cells and modulating the TGF-β-associated pathway in liver fibrosis."

Journal • Preclinical • Fibrosis • Hepatology • Immunology • Liver Cirrhosis • Liver Failure • CAT • CD44 • MRC1 • TGFB1

Mitochondrial uncoupling inhibits serine catabolism via FTO activation in metastatic breast cancer. (PubMed, Cancer Biol Med) - "The findings herein demonstrated that mitochondrial uncouplers inhibit MSCP through FTO-dependent m6A demethylation. This work identified mitochondrial uncoupling as a novel and promising therapeutic approach for promoting m6A demethylation and targeting MSCP in metastatic breast cancer."

Journal • Breast Cancer • Genetic Disorders • Obesity • Oncology • Solid Tumor • Triple Negative Breast Cancer • FTO • MTHFD2 • SHMT2

STAT3 Inhibition Ameliorates Cognitive Dysfunction in Type 2 Diabetes Mellitus by Modulating Astrocytes via Nrf2 Pathway Activation. (PubMed, Free Radic Biol Med) - "This study investigated the therapeutic potential of targeting STAT3 in TDACD using both pharmacological inhibition with niclosamide and specific genetic silencing strategies...Crucially, silencing Nrf2 eliminated the protective effects of STAT3 inhibition, suggesting a functional regulatory axis between STAT3 and Nrf2. Collectively, our findings support that STAT3 inhibition ameliorates cognitive dysfunction by disinhibiting the Nrf2 pathway to restore redox homeostasis and shift astrocytes towards a neuroprotective phenotype, highlighting the STAT3-Nrf2 axis as a promising therapeutic target for TDACD."

Journal • CNS Disorders • Cognitive Disorders • Diabetes • Inflammation • Metabolic Disorders • Type 2 Diabetes Mellitus

Mast Cell-Derived CXCL4: A Key Mediator of Ferroptosis and Cardiac Damage in Septic Cardiomyopathy. (PubMed, Immun Inflamm Dis) - "Mast cell-derived CXCL4 induces macrophage ferroptosis via the STAT3/P53 signaling pathway, impairs macrophage phagocytic function, and exacerbates myocardial injury in SCM. Targeting mast cell activation, CXCL4 release, or the STAT3/P53-ferroptosis axis may serve as promising therapeutic strategies for SCM."

Journal • Cardiomyopathy • Cardiovascular • Heart Failure • Infectious Disease • Inflammation • Septic Shock • CD36 • GPX4 • MERTK • SCARB1 • SLC7A11

From anthelmintic to neurotherapeutic: exploring the regenerative potential of niclosamide in sciatic nerve injury. (PubMed, Inflammopharmacology) - No abstract available

Journal • Neuralgia • Pain

2-Deoxyglucose dendrimer-enabled niclosamide delivery to FRβ-expressing macrophages alleviates endometriosis progression and associated hyperalgesia. (PubMed, bioRxiv) - "A single intraperitoneal dose of FA-2DG-D-Niclo (25 or 50 mg/kg/bw of niclosamide) significantly reduced FRβ⁺ macrophage burden, suppressed lesion number and volume, and markedly improved endometriosis-associated hyperalgesia at two weeks post-treatment. Together, these findings establish FRβ⁺ macrophages as a potential target in endometriosis and present FA-2DG-D-Niclo as a non-hormonal, macrophage-focused nanomedicine for precise and effective endometriosis treatment."

Journal • Endometriosis • Gynecology • Inflammation • Women's Health

Nanoengineered Niclosamide as a Microenvironment Modulator for Spinal Cord Regeneration: A Hypothetical Roadmap Toward Brain/Head Transplant Feasibility. (PubMed, Wiley Interdiscip Rev Nanomed Nanobiotechnol) - "This Perspective proposes nanoengineered niclosamide, a repurposable multi-pathway modulator, as a strategy to reprogram this niche. By attenuating NF-κB/STAT3-driven inflammation, suppressing fibrotic signaling, and reducing ECM rigidity, nanoengineered niclosamide may synergize with scaffold- and stimulation-based approaches, highlighting microenvironmental modulation as a realistic path forward for SCI repair."

Journal • Review • CNS Disorders • Fibrosis • Inflammation • Orthopedics • Transplantation • STAT3

Enzymatic Glucosylation Enhances the Solubility of Niclosamide but Abrogates Its Therapeutic Efficacy. (PubMed, ACS Omega) - "This would preserve the solubility benefit afforded by glycosylation and release the therapeutically active Nic at the desired site. This work provides evidence that glycosylation is a viable strategy for improving the solubility of Nic, and that the development of an enzymatic glycosylation reaction is feasible as a means for the bioproduction of Nic-Glc."

Journal • Hepatitis C • Infectious Disease • Novel Coronavirus Disease • Oncology • Respiratory Diseases

Investigation of quantum chemical studies of niclosamide in different solvents using DFT calculations. (PubMed, J Mol Model) - "Orbital composition analysis with Mulliken partition was performed to determine the percentage contribution of atomic orbitals to HOMO and LUMO. Additionally, UV-Vis absorption spectra were examined in various phases to investigate the effects of solvent and environment on electronic transitions."

Journal • Oncology

The Effect of Intranasal Niclosamide on Nasal Symptoms in Patients with Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis. (PubMed, Arthritis Rheumatol) - "These data are a signal of potential clinical effect on ENT manifestations in AAV. They support a role for the IL6/STAT3 pathway in AAV; intranasal niclosamide or other drug candidates in this pathway warrant further evaluation."

Journal • ANCA Vasculitis • Infectious Disease • Novel Coronavirus Disease • Vasculitis • IL6

Canonical and noncanonical NF-κB signaling in uveal melanoma: mechanisms, microenvironment, and therapeutic modulation. (PubMed, Med Hypothesis Discov Innov Ophthalmol) - "Canonical NF-κB signaling is mechanistically related to UM cell survival, proliferation, and migration, as shown by pharmacologic inhibition like BAY11-7082, and niclosamide and genetic modulation like microRNA-9. NF-κB signaling, particularly the canonical branch, is required for UM malignancy, while noncanonical signaling is linked with high-risk features. Branch-specific genetic manipulations and clinically relevant models should be employed in future research to maximize therapeutic strategies."

Journal • Review • Eye Cancer • Melanoma • Ocular Melanoma • Oncology • Solid Tumor • Targeted Protein Degradation • Uveal Melanoma • BAP1 • TNFA

BAM 15 Exerts Molluscicidal Effects on Pomacea canaliculata Through the Induction of Oxidative Stress, Impaired Energy Metabolism, and Tissue Damage. (PubMed, Molecules) - "Our findings reveal that BAM 15 operates via a three-stage mechanism: (1) it disrupts membrane potential (ΔΨm) and impairs ATP production, severely disturbing energy metabolism; (2) energy deficits stimulate excessive electron transport chain activity, generating reactive oxygen species (ROS) and initiating oxidative stress; (3) persistent metabolic imbalance and oxidative damage culminate in extensive tissue injury. These results identify BAM 15 as a promising candidate for molluscicide development."

Journal

Highly sensitive niclosamide detection using the multifunctional carbon nanoflowers@halloysite nanotubes@graphene nanoplates nanocomposite modified electrochemical sensor. (PubMed, Food Chem) - "The CNF@Hal@Gr/GCE sensor exhibited ultrasensitive NA detection performance, including wide linear range (0.01-20 μM) and low limit of detection (5.83 nM). Moreover, the CNF@Hal@Gr/GCE sensor presented superior practical applicability with relative standard deviations of 0.87-4.71% and recoveries of 95.18-103.1%."

Journal

Niclosamide Encapsulated pH-Responsive Polyzwitterionic Block Copolymers for Cancer Therapy. (PubMed, Macromol Biosci) - "ZIP-NIC exhibited similar anti-cancer efficacy to free NIC in the HCT116 cell line. Our results suggest that polyzwitterionic nanoparticles constitute a promising class of materials to deliver antitumor drugs and warrant further investigation."

Journal • Oncology

Strategic Preparedness of Broad-Spectrum Antivirals for Rapid Response Towards Next Pandemics. (PubMed, Small Sci) - "Several repurposed drugs, such as niclosamide, favipiravir, remdesivir, nitazoxanide, and zinc-ionophores, have demonstrated potential broad-spectrum activity when formulated at the nanoscale. Such nanotechnological strategies not only improve antiviral efficacy across multiple viral families, including Coronaviridae, Flaviviridae, Orthomyxoviridae, and Poxviridae, but also support scalable, cost-effective production suitable for global deployment. By integrating drug repurposing with nanoengineering, BSAs can form the cornerstone of future pandemic preparedness, bridging the gap between laboratory innovation and rapid clinical response to emerging infectious diseases."

Journal • Infectious Disease • Novel Coronavirus Disease

Novel niclosamide-derived Schiff bases as a dual-targeted anticancer agents. (PubMed, Sci Rep) - No abstract available

Journal • Oncology

Chronic Exposure to Niclosamide Disrupts Structure and Metabolism of Digestive Glands and Foot in Cipangopaludina cathayensis. (PubMed, Biology (Basel)) - "At the population level, persistent niclosamide exposure may destabilize mollusk trophic-level populations, ultimately leading to ecological consequences. Our findings demonstrate the toxicological risks of niclosamide to freshwater mollusks."

Journal • Infectious Disease • Muscular Atrophy

Electro-Stimulated Graphene-Polymer Nanocomposites Enable Wearable Patches With Feedback-Controlled Drug Release. (PubMed, Adv Healthc Mater) - "Stimuli-responsive nanomaterials capable of spatiotemporal control over drug release are of nanocomposite patch ("e-Medi-Patch") engineered from biodegradable polycaprolactone (PCL), graphene nanoplatelets, and a redox-active therapeutic, niclosamide...Beyond melanoma, the platform accommodates other redox-active therapeutics and offers scalable melt-blending fabrication. This work establishes an integrated materials-electronics strategy for wearable, feedback-controlled drug delivery, bridging multifunctional nanocomposites and precision medicine."

Journal • Melanoma • Oncology • Solid Tumor

Spray Drying for Pharmaceutical Raw Materials: A Systematic Review on Enhancing Bioavailability and Stability. (PubMed, Drug Des Devel Ther) - "S-SNEDDS produced AUC enhancements of 4-9.9-fold (sorafenib approximately 4.6-fold, enzalutamide approximately 7-fold, niclosamide approximately 9.9-fold). Ongoing deficiencies encompass inadequate carrier comparisons, insufficient mechanistic comprehension of drying kinetics, and issues related to scale-up and regulation. This review offers mechanistic insights and a standardized approach to facilitate future formulation development."

Journal • Review